MSGene

MSGene - Gene overview of all published MS-association studies for CD58

Gene:

CD58 (RP5-1086K13.2; FLJ23181; FLJ43722; LFA-3; LFA3)

Protein:

CD58 molecule (CD58 antigen, (lymphocyte function-associated antigen 3); surface glycoprotein LFA-3)

Chromosome:

1 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 25 November 2011 ;

***Note that content for MSGene is still being curated and that most currently displayed pages (including this page) contain preliminary summaries and are still incomplete.***

1. Case-Control Studies (by ethnic group)
				MS Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result
Caucasian
ANZgene, 2009	Overlaps with IMSGC, 2011 (ANZ-GWAS)	CL,PO	1 (detail)	1618 (72%)	O/M	34.1 (7-67)	-	3413 (-)	-	n.a.
ANZgene, 2009	Overlaps with IMSGC, 2011 (Australia, New Zealand)	CL	1 (detail)	2256 (78%)	O/M	34.5 (4-73)	-	2310 (-)	-	n.a.
Aulchenko, 2008	Netherlands (GWAS)	CL	1 (detail)	45 (-)	O/M	-	-	195 (-)	-	Negative
Baranzini, 2008	Overlaps with IMSGC, 2011 (GeneMSA-GWAS)	CL	8 (detail)	978 (67%)	MD1&2	34 (11-61)	47 (21-69)	883 (66%)	46 (21-69)	Negative
Brynedal, 2009	Sweden	CL	9 (detail)	1077 (-)	U	-	-	1217 (-)	-	Positive
De Jager, 2009	Belgium	CL	2 (detail)	368 (63%)	MD1	35 (10-65)	51 (-)	372 (-)	-	Negative
De Jager, 2009	Finland	CL	2 (detail)	715 (71%)	MD1	-	-	727 (-)	-	Negative
De Jager, 2009	UK	CL	2 (detail)	961 (73%)	MD1	33 (13-60)	46 (-)	2466 (-)	-	Negative
De Jager, 2009	USA (CA)	CL	2 (detail)	1557 (-)	MD1	-	-	855 (-)	-	Positive
De Jager, 2009	Overlaps with IMSGC, 2011 (BWH)	CL	30 (detail)	707 (75%)	MD1	33 (10-69)	45 (-)	-	-	Positive
D'Netto, 2009	Canada	CL	1 (detail)	43 (-)	U	-	-	182 (-)	-	Positive
Hoppenbrouwers, 2008	Overlaps with Aulchenko, 2008	CL	1 (detail)	46 (72%)	U	33 + 11 (-)	-	194 (-)	-	n.a.
Hoppenbrouwers, 2009	Netherlands (outbred)	CL	1 (detail)	490 (-)	O/M	-	-	426 (-)	-	Positive
Hoppenbrouwers, 2009	Overlaps with Aulchenko, 2008	CL	1 (detail)	45 (-)	O/M	-	-	195 (-)	-	n.a.
IMSGC, 2007	USA, UK (GWAS)	CL,PO	2 (detail)	931 (75%)	MD1&2	27.8 (10-51)	38.6 (17-59)	2431 (-)	-	Positive
IMSGC, 2007	Overlaps with De Jager, 2009 (UK)	CL	1 (detail)	928 (73%)	MD1&2	32.6 (13-60)	45.1 (17-79)	1475 (-)	-	n.a.
IMSGC, 2007	Overlaps with De Jager, 2009 (USA)	CL	1 (detail)	1394 (73%)	MD1&2	33.1 (3-69)	45.4 (18-74)	1512 (-)	-	n.a.
IMSGC, 2011	Europe, USA, Australia, New Zealand (WTCCC2-GWAS)	CL,PO	1 (detail)	9722 (-)	U	32.3 (-)	44.8 (-)	17376 (-)	-	Positive
IMSGC, 2011	Netherlands (GeneMSA-GWAS)	CL	1 (detail)	230 (74%)	U	33 (-)	46 (-)	232 (-)	-	Negative
IMSGC, 2011	USA (GeneMSA-GWAS)	CL	1 (detail)	486 (76%)	U	33 (-)	48 (-)	431 (-)	-	Negative
IMSGC, 2011	Switzerland (GeneMSA-GWAS)	CL	1 (detail)	253 (74%)	U	33 (-)	45 (-)	208 (-)	-	Negative
IMSGC, 2011	Australia, New Zealand (ANZ-GWAS)	CL	1 (detail)	1618 (72%)	U	34 (-)	-	1988 (-)	-	Negative
IMSGC, 2011	USA (BWH-GWAS)	CL	1 (detail)	973 (72%)	U	33 (-)	47 (-)	2952 (-)	-	Negative
IMSGC, 2011	UK, USA (IMSGC2007-GWAS)	CL,PO	1 (detail)	795 (76%)	U	28 (-)	41 (-)	1679 (-)	-	Negative
Perera, 2009	Overlaps with Rubio, 2008	CL	1 (detail)	1146 (-)	O/M	-	-	1309 (-)	-	Positive
Rubio, 2008	Australia	CL	1 (detail)	1146 (75%)	O/M	32 (7-67)	-	1309 (-)	-	Positive
Sanna, 2010	Italy-Sardinia (GWAS)	CL	1 (detail)	882 (-)	MD1	-	-	872 (-)	-	Positive
African Descent
Johnson, 2009	USA	CL	2 (detail)	918 (79%)	MD1	-	-	656 (71%)	-	Negative
Other/Mixed
Pandit, 2010	India	CL	1 (detail)	197 (48%)	MD1	30 + 5.6 (-)	35.4 + 3.2 (-)	197 (49%)	31.2 + 4.4 (-)	Negative

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

2. Family-Based Studies (by ethnic group)
				Affecteds				Unaffecteds
Study	Population	# Polys	# Families	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result
Caucasian
De Jager, 2009	Australia	2 (detail)	372	-	MD1	33 (7-55)	42 (-)	-	-	Positive
De Jager, 2009	Belgium	2 (detail)	134	-	MD1	28 (9-45)	38 (-)	-	-	Positive
De Jager, 2009	USA, UK	14 (detail)	1278	-	MD1	-	-	-	-	Positive
D'Netto, 2009	Overlaps with D'Netto, 2009 (CC)	1 (detail)	43	211 (-)	U	-	-	-	-	Positive
Hoppenbrouwers, 2009	Canada	1 (detail)		1318 (-)	O/M	-	-	1507 (-)	-	Positive
IMSGC, 2007	Overlaps with De Jager, 2009 (UK)	1 (detail)	380	380 (75%)	MD1&2	27.4 (10-53)	37.4 (17-58)	-	-	n.a.
IMSGC, 2007	Overlaps with De Jager, 2009 (USA)	1 (detail)	229	229 (79%)	MD1&2	31.1 (9-51)	39.4 (19-58)	-	-	n.a.
IMSGC, 2007	Overlaps with IMSGC, 2007 (UK-GWAS, CC)	1 (detail)	453	453 (75%)	MD1&2	26.5 (10-48)	38.2 (19-59)	-	-	Positive
IMSGC, 2007	Overlaps with IMSGC, 2007 (USA-GWAS, CC)	1 (detail)	478	478 (74%)	MD1&2	29 (11-51)	39 (17-57)	-	-	Positive

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine MS diagnosis -> "P" (Poser criteria, 1983), "MD1" (McDonald criteria, 2001), "MD2" (revised McDonald criteria, 2005), "MD1&2" (McDonald criteria, 2001 and 2005), "O/M" (other/mixed), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.

Print this page

Email this page

MSDF RSS

Text size

Share & Bookmark

MSGene Recent Updates

MSGene Top Results